Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Nova Mentis Life Sciences Corp (OP: NMLSF ) 0.0114 -0.0008 (-6.56%) Streaming Delayed Price Updated: 9:52 AM EDT, Jun 24, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 335 Open 0.0114 Bid (Size) N/A (0) Ask (Size) N/A (0) Prev. Close 0.0122 Today's Range 0.0114 - 0.0114 52wk Range 0.0077 - 0.0370 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More April 24, 2023 LSD Trial Study Shows Potential For Major Depression Psychedelics biopharma company Mind Medicine Inc. (NASDAQ: MNMD) recently shared positive topline data from an advanced clinical trial of LSD as a... Via Benzinga Psychedelics And The Spectrum: Groundbreaking Study Details How One Firm Approaches Autism April 20, 2023 The partnership between contract research organization KGK Sciences Inc. and Nova Mentis Life Science Corp. (OTC: NMLSF) has started < Via Benzinga Performance YTD -10.24% -10.24% 1 Month -12.31% -12.31% 3 Month -11.63% -11.63% 6 Month -5.79% -5.79% 1 Year -59.86% -59.86% More News Read More Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More February 21, 2023 Via Benzinga Health Canada Grants Exemption: Phase 2 Trial On Psilocybin For Genetic Disorder February 14, 2023 Via Benzinga Nova Mentis Is Looking To Treat Autism With Psilocybin April 07, 2022 Via Benzinga First-Ever Clinical Trial On Magic Mushroom Therapy For Autism's Genetic Cause Receives Approval December 27, 2022 Via Benzinga Psyched: Fed Guidelines And Research Production Quotas, Protests In Canada, Cal's Decrim Project December 06, 2022 Via Benzinga Psychedelic Partnership To Test Psilocybin For FXS In First Phase 2 Clinical Trial November 30, 2022 Via Benzinga Psychedelics For FXS Symptoms: New Research Contract For Upcoming Phase 2 Clinical Trial November 17, 2022 Via Benzinga Psyched: Autopsy Reveals Death By Ketamine, LSD-Like Drugs Without Hallucinations, DEA & Right To Try Psilocybin September 30, 2022 Via Benzinga Magic Mushroom In A Pill? New Microdose Plans Enter Clinical Studies: Here's What Scientists Want To Learn September 29, 2022 Via Benzinga Nova Mentis Psilocybin Microdose Capsule Formulation to be Submitted in Health Canada Phase 2A Clinical Trial Application September 29, 2022 Via Newsfile New Batch Of Psilocybin Microdose Capsules Is Ready, Learn All The Details September 17, 2022 Via Benzinga Nova Mentis Completes Production of Psilocybin Microdose Capsules September 15, 2022 Via Newsfile More Patent Applications For Psilocybin: Learn About NOVA's Psychedelic Treatments For Neurological Diseases June 16, 2022 Via Benzinga Psyched: Christie's Launches NFT Collection Supporting Psychedelic Science, Origin's Listing On CSE Gives Retail Investors Access To Private Companies June 08, 2022 Via Benzinga Nova Mentis NM-1001 Psilocybin Compound Gets DEA Approval For Export, Here's What Happened June 07, 2022 Via Benzinga Psyched: Psilocybin Therapy Effective After One Year, Cybin & Deepak Chopra, Enveric Psilocybin Cancer Study February 22, 2022 Via Benzinga This Psychedelics Penny Stock Is Up 55% After Successful Study On Microdosing For Autism February 16, 2022 Via Benzinga Wellbeing Digital Sciences' Integrated Approach Aims To Capture Emerging Mental Health Tech And Psychedelics Market February 08, 2022 Via Benzinga Wellbeing Digital Sciences' Subsidiary KGK Science Forms Tactical Partnership With Nova Mentis January 27, 2022 Via Benzinga Psyched: Detroit Decriminalizes Psychedelics, Compass To Study Psilocybin For PTSD, Filaments Gets First-Ever FDA Approval November 08, 2021 Via Benzinga Exposures Product Safety Psyched: British PM Considers Psychedelics, New Partnership To Study Psilocybin For Autism, Compass Gets Another Patent October 26, 2021 Via Benzinga Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation October 18, 2021 Via Benzinga There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are October 13, 2021 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
